Euroapi: net loss in H1
(CercleFinance.com) - Euroapi reports a net loss of -E34.
8m for H1 2024, compared with +E62.8m a year earlier, and a Core EBITDA that is down 23.8% to E47.6m, giving a margin of 10.6%, compared with 12.6% in H1 2023.
Sales fell 9.6% to E448.7m, were marked by the sharp drop in Sanofi volumes and the suspension of production at Brindisi, which overshadowed the positive momentum of sales to customers other than Sanofi.
The active pharmaceutical ingredients supplier considers the execution of its FOCUS-27 plan to be on track, and confirms its targets for 2024 of a Core EBITDA margin of between 4% and 7%, and a LFL sales decline of between -8% and -11%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
8m for H1 2024, compared with +E62.8m a year earlier, and a Core EBITDA that is down 23.8% to E47.6m, giving a margin of 10.6%, compared with 12.6% in H1 2023.
Sales fell 9.6% to E448.7m, were marked by the sharp drop in Sanofi volumes and the suspension of production at Brindisi, which overshadowed the positive momentum of sales to customers other than Sanofi.
The active pharmaceutical ingredients supplier considers the execution of its FOCUS-27 plan to be on track, and confirms its targets for 2024 of a Core EBITDA margin of between 4% and 7%, and a LFL sales decline of between -8% and -11%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.